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PTV/r), ombitasvir (OBV), and dasabuvir (DSV) are direct-acting with the 3D regimen of OBV, PTV/r, and DSV without dose adjust-
antiviral agents (DAAs) for the treatment of chronic hepatitis C
virus (HCV) infection. Thirteen studies were conducted to charac-
terize drug-drug interactions for the 3D regimen of OBV, PTV/r,
and DSV and various medications in healthy volunteers to inform
dosing recommendations in HCV-infected patients.
Methods:Mechanism-based drug-drug interactions were evalu-
ated for gemﬁbrozil, ketoconazole, carbamazepine, warfarin,
omeprazole, digoxin, pravastatin, and rosuvastatin. Drug-drug
interactions with medications commonly used in HCV-infected
patients were evaluated for amlodipine, furosemide, alprazolam,
zolpidem, duloxetine, escitalopram, methadone, buprenorphine/
naloxone, and oral contraceptives. Ratios of geometric means
with 90% conﬁdence intervals for maximum plasma concentra-
tion (Cmax) and area under the plasma concentration-time curve
(AUC) were used to determine the magnitude of interaction.
Results: Coadministration with the 3D regimen of OBV, PTV/r,
and DSV resulted in a <2-fold change in mean Cmax and AUC for
most medications and the DAAs, indicating minimal to modest
interactions. Carbamazepine decreased PTV, ritonavir, and DSV
exposures substantially, while gemﬁbrozil increased DSV expo-
sures substantially. Although coadministration with ethinyl
estradiol-containing contraceptives resulted in elevated alanine
aminotransferase levels, coadministration with a progestin-only
contraceptive did not.Journal of Hepatology 20
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no dose adjustment is necessary for the 3D regimen when coad-
ministered with 17 of the 20 medications, coadministration with
gemﬁbrozil, carbamazepine, or ethinyl estradiol-containing con-
traceptives is contraindicated.
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by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
The risk of morbidity and mortality related to chronic hepatitis C
virus (HCV) infection is markedly reduced in patients who
achieve a sustained virologic response (SVR) with antiviral ther-
apy [1–4]. Recently, development of direct-acting antiviral agents
(DAAs) targeting various steps in the HCV life cycle has led to
substantial improvements in efﬁcacy and reductions in toxicity
compared to prior interferon-based therapies. However, judicious
use of these DAAs requires strict attention to drug-drug interac-
tions because all HCV combination regimens interact with drug
metabolizing enzymes, drug transporters, or both [5].
Knowledge of drug-drug interactions is important for appropriate
clinical management, which sometimes requires dose adjust-
ments or discontinuation of contraindicated medications [6,7].
Paritaprevir (ABT-450, PTV) is a nonstructural (NS) protein
3/4A protease inhibitor. PTV is metabolized primarily by cyto-
chrome P450 (CYP) 3A and is given with a low dose of the
CYP3A inhibitor, ritonavir, as a pharmacokinetic enhancer to
achieve higher peak, trough, and overall PTV exposures. This
enables once daily (QD) administration and use of lower PTV
doses thanwould be necessary without ritonavir. The use of riton-
avir also limits the potential for further interaction of PTV with
other CYP3A inhibitors. Ombitasvir (ABT-267, OBV) is a potent
NS5A inhibitor and dasabuvir (ABT-333, DSV) is an NS5B
non-nucleoside polymerase inhibitor. Phase 3 clinical trials of
the combination of these three DAAs (3D regimen of OBV, PTV/r,
and DSV) with andwithout ribavirin have demonstrated SVR rates
12 weeks after the end of treatment of 92% to 100%, in cirrhotic
and noncirrhotic HCV genotype 1-infected subjects [8–11].
In vitro data indicate PTV and ritonavir are primarily metabo-
lized by CYP3A, while DSV is primarily metabolized by CYP2C8
[12]. DSV may also undergo metabolism by CYP3A. Ombitasvir15 vol. 63 j 20–29
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is predominantly metabolized by amide hydrolysis followed by
oxidative metabolism. Ritonavir is a CYP3A inhibitor, while the
DAAs do not inhibit CYP enzymes. In vitro data also suggest that
at clinically relevant concentrations, PTV is an organic anion
transporting polypeptide (OATP) 1B1/B3 inhibitor and PTV, riton-
avir, and DSV are potential inhibitors of P-glycoprotein (P-gp) and
breast cancer resistance protein (BCRP) [12]. The DAAs and riton-
avir are in vitro substrates of P-gp and BCRP, and PTV is also a
substrate of OATP1B1/B3.
A broad drug-drug interaction program was conducted in
healthy volunteers to evaluate the potential for interactions with
the 3D regimen of OBV, PTV/r, and DSV. These studies character-
ized mechanism-based interactions and interactions that may
occur with medications commonly used in HCV-infected patients.
Mechanism-based interactions, which characterize interactions
associated with speciﬁc enzymes or transporters, were evaluated
using standard probe substrates, inhibitors, or inducers. Results
from these interactions can be used to predict interactions and
provide dosing recommendations for other medications that
share the same metabolic and transporter pathways.
Mechanism-based interaction studies evaluated the following
enzymes and transporters: CYP2C9 and 2C19 (substrates: war-
farin, omeprazole), CYP2C8 (inhibitor: gemﬁbrozil), CYP3A and
P-gp (inhibitor: ketoconazole; inducer: carbamazepine), P-gp
(substrate: digoxin), OATP1B1/B3 (substrate: pravastatin), and
OATP1B1/B3 plus BCRP (substrate: rosuvastatin). The substrates,
inhibitors, and inducers chosen for evaluation were based onTable 1. Medications evaluated in drug-drug interaction studies with the 3D regime
Mechanism-based drug interactions
Drug class N Medication (dose) M
Antihyperlipidemics 12 Gemfibrozil* (600 mg BID) E
Antifungals 12 Ketoconazole (400 mg QD) E
Anticonvulsants 12 Carbamazepine (200 mg QD and BID) E
Anticoagulants 12 Warfarin (5 mg) E
Acid reducing agents 12 Omeprazole (40 mg QD) E
Antiarrhythmics 12 Digoxin (0.5 mg) E
Statins 12 Pravastatin (10 mg QD) E
12 Rosuvastatin (5 mg QD) E
Drug interactions with commonly used medications
Drug class N Medication (metabolic pathway) (dose)
Anti-addictives 12 Methadone (CYP3A4/CYP2B6 substrate) 
prescription)
13 Buprenorphine/naloxone (CYP3A4; UGT1
24/6 mg per physician’s prescription)
Antidepressants 12 Escitalopram (CYP3A4/CYP2C19 substra
12 Duloxetine (CYP2D6/CYP1A2 substrate a
Antihypertensives 14 Amlodipine (CYP3A4 substrate) (5 mg)
Anxiolytics/sleep aids 12 Alprazolam (CYP3A4 substrate) (0.5 mg)
12 Zolpidem (CYP3A4 substrate) (5 mg)
Diuretics 12 Furosemide (UGT1A1 substrate) (20 mg)
Oral contraceptives 12 Norethindrone (UGT/CYP3A4/sulfo-transf
9 Ethinyl estradiol + norgestimate† (UGT/CY
12 Ethinyl estradiol + norethindrone (UGT/CY
UGT, uridine diphospho-glucuronosyltransferase; QD, once daily; BID, twice daily.
*Evaluated with a PTV/r + DSV regimen only.
Evaluated with PTV/r, OBV ± DSV regimens.
Journal of Hepatology 20regulatory guidance from the United States Food and Drug
Administration and the European Medicines Agency [13,14].
Drug-drug interactions with commonly used medications rep-
resenting the drug classes of antidepressants (escitalopram and
duloxetine), antihypertensives (amlodipine), diuretics (furose-
mide), anxiolytics/sleep aids (alprazolam and zolpidem), and oral
contraceptives (norethindrone, ethinyl estradiol [EE] plus norges-
timate, and EE plus norethindrone) were studied to assess poten-
tial for drug interaction and to provide dosing recommendations
for these drugs in patients taking the 3D regimen of OBV, PTV/r,
and DSV. Methadone and buprenorphine/naloxone, which are
commonly used as opioid substitutions in patients with a history
of drug addiction, were also evaluated.Materials and methods
Study designs
Thirteen open-label, Phase 1 clinical studies were conducted at ﬁve clinical study
sites in accordance with Good Clinical Practice guidelines and ethical principles
that have their origin in the Declaration of Helsinki. All study protocols and
amendments were approved by the institutional review boards at each site and
written informed consent was obtained from each subject before any
study-related procedures were performed.
Enrolled subjects were healthy adult male or female volunteers, between the
ages of 18 and 55 years, with a body mass index between 18 and 30 kg/m2.
Metabolic enzyme and drug transporter inhibitors or inducers were not allowedn of OBV, PTV/r, and DSV.
echanism
ffect of CYP2C8 inhibition by gemfibrozil on PTV/r and DSV
ffect of CYP3A and P-gp inhibition by ketoconazole on 3D
ffect of CYP3A induction by carbamazepine on 3D
ffect of CYP2C9 inhibition/induction by 3D on warfarin
ffect of CYP2C19 inhibition/induction by 3D on omeprazole
ffect of P-gp inhibition by 3D on digoxin
ffect of OATP1B1/B3 inhibition by 3D on pravastatin
ffect of OATP1B1/B3 + BCRP inhibition by 3D on rosuvastatin
(individualized QD dosing 20 to 120 mg per physician’s 
A1 substrate/UGT substrate) (individualized QD dosing 4/1 mg to 
te) (10 mg)
nd CYP1A2 inhibitor) (60 mg)
erases substrate) (0.35 mg)
P3A4/sulfo-transferases substrate) (35 µg/0.250 mg)
P3A4/sulfo-transferases substrate) (35 µg/0.4 mg)
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Fig. 1. Study designs used for evaluating the 20 drug interactions. For more
details on the study designs, refer to Table 2.
Table 2. Dosing days in different study periods in Fig. 1.
Study design* Medication A
I Gemfibrozil† Days 4-5
I Ketoconazole Days 8-9
I Carbamazepine Days 1-3 (QD)
Days 4-21 (BID)
II Digoxin Days 11-24
II Warfarin Days 15-28
II Furosemide Days 3-16
II Amlodipine Days 11-24
II Escitalopram Days 7-20
II Duloxetine Days 7-20
II Alprazolam Days 4-17
II Zolpidem Days 3-16
II Omeprazole Days 6-19
V EE/NGM‡ Days 1-9
V EE/NET Days 1-7
V NET Days 1-3
QD, once daily; BID, twice daily; EE/NGM, ethinyl estradiol and norgestimate; EE/NET, e
*See Fig. 1.
Evaluated with a PTV/r + DSV regimen only.
Evaluated with PTV/r, OBV ± DSV regimens.
§Study drug discontinued on Day 15.
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buprenorphine/naloxone studies were on stable methadone and buprenorphine/
naloxone maintenance therapy, respectively, for a minimum of 14 days before the
screening visit.
Drug-drug interactions were evaluated for the 3D regimen of OBV, PTV/r, and
DSV using 20 drugs from a wide variety of drug classes (Table 1). The doses of
PTV/r and OBV were 150 mg/100 mg and 25 mg, respectively and the dose of
DSV was 250 mg or 400 mg (Phase 2 formulation), which provided comparable
DSV exposures. The regimen evaluated in these studies is the same as that tested
in Phase 3 clinical trials for treatment of HCV genotype 1 infection.
Most evaluations were conducted under multiple dosing conditions (PTV/r
and OBV QD and DSV twice daily [BID]), although a few mechanism-based inter-
actions were evaluated under single dosing conditions (Fig. 1 and Table 2). For all
evaluations, the 3D regimen was coadministered with the interacting drug after a
moderate-fat meal (approximately 1900 to 2300 calories/day with 40% of calories
from fat).
Key elements of the study designs are presented in Fig. 1 and Table 2. All eval-
uations were conducted with the 3D regimen of OBV, PTV/r, and DSV except for
the study with gemﬁbrozil, which evaluated interactions only with PTV/r plus
DSV. OBV and gemﬁbrozil are not expected to interact with each other as their
metabolic pathways do not overlap.
Safety and tolerability assessments
Safety and tolerability were assessed throughout each study based on adverse
event monitoring, vital signs measurements, physical examinations, electrocar-
diogram assessments, and laboratory tests.
Pharmacokinetic assessments
Blood samples for determination of plasma concentrations of PTV, ritonavir, OBV,
DSV, DSV metabolite M1, and the interacting medications and their metabolites, if
applicable, were collected by venipuncture. Plasma concentrations were deter-
mined using validated liquid chromatography with tandem mass spectrometric
detection methods. The lower limits of quantitation (LLOQs) for PTV, ritonavir,
OBV, DSV, and DSV M1 were approximately 0.6 ng/ml, 4.7 ng/ml, 0.4 ng/ml,
4.4 ng/ml, and 4.6 ng/ml, respectively. The LLOQs for the concomitantDays of dosing
B C
Day 6 Days 7-8
Day 10 Days 11-13
Day 22 Days 23-24 (BID)
Day 25 Days 26-29
Day 29 Days 30-38
Day 17 Day 18
Day 25 Days 26-34
Day 21 Days 22-26
Day 21 Day 22
Day 18 Days 19-21
Day 17 Day 18
Days 20-24 n.a.
Days 10-21 Days 22-28
Days 8-21§ Days 22-28
Days 4-17 Days 18-24
thinyl estradiol and norethindrone; NET, norethindrone; n.a., not applicable.
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medications were 0.003 ng/ml (EE), 0.01 ng/ml (digoxin), 0.02 ng/ml (naloxone,
norelgestromin, norgestrel), 0.05 ng/ml (amlodipine, S-desmethylcitalopram),
0.1 ng/ml (alprazolam, buprenorphine, norbuprenorphine, ketoconazole,
norethindrone, rosuvastatin), 0.2 ng/ml (escitalopram), 0.25 ng/ml (zolpidem),
0.5 ng/ml (duloxetine, pravastatin), 1 ng/ml (R- and S-methadone, omeprazole),
5 ng/ml (R- and S-warfarin, furosemide), and 50 ng/ml (carbamazepine,
carbamazepine-10-11-epoxide). For digoxin, urine was also collected and the
excreted fraction of drug was measured (LLOQ of 2 ng/ml).
Pharmacokinetic analyses were performed by noncompartmental methods
using PhoenixWinNonlinVersion 6.0 or above (Certara, St. Louis, MO). The pri-
mary pharmacokinetic parameters were maximum observed plasma concentra-
tion (Cmax) and area under the plasma concentration-time curve (AUC) during a
dosing interval (AUC12 for BID administration; AUC24 for QD administration) or
from time zero to inﬁnity (AUC1 for single dose). Additional pharmacokinetic
parameters include: time to Cmax (Tmax), trough concentration (Ctrough), and ter-
minal phase elimination half-life (t1/2).
Pharmacodynamic assessments
For the methadone and buprenorphine/naloxone interaction studies, pharmaco-
dynamic measurements were performed to monitor for signs of withdrawal trig-
gered by possible changes in methadone and buprenorphine/naloxone exposures,
during coadministration with OBV, PTV/r, and DSV. Pupil diameter and two
self-administered instruments (short opiate withdrawal scale score and the
desire for drugs questionnaire) were measured at various time points before
and during coadministration.
Statistical analyses
Statistical analyses were conducted using SAS, Version 9.2 (Cary, NC). Effects of
the 3D regimen of OBV, PTV/r, and DSV on the interacting medications and vice
versa were estimated by analyzing loge-transformed Cmax and AUC values under
a repeated measures analysis framework. Geometric mean ratios (GMRs) and 90%
conﬁdence intervals (CIs) for Cmax and AUC were calculated to quantify the mag-
nitude of interaction.Results
Subject demographics
A total of 228 subjects, 67% of whom were male, received at least
one dose of study drug. Across studies, 64.0% of subjects were
white, 31.6% were black, and 4.4% were other races.
Demographics of subjects across the 13 studies were similar:
the age of subjects ranged from 20 to 55 years, mean age ranged
from 29.5 to 39.1 years, and median body weight ranged from
67.6 to 83.7 kg.
Pharmacokinetics
Mechanism-based drug-drug interactions
Results from studies of mechanism-based interactions of substra
tes/inhibitors/inducers of CYPs and transporters on DAA and
ritonavir exposures and vice versa are shown in Figs. 2 and 3
and discussed below.
CYP2C8 inhibitor (gemﬁbrozil)
Coadministration of PTV/r plus DSV with gemﬁbrozil did not
affect exposures of ritonavir, but increased PTV Cmax and AUC
(21% and 38%, respectively) as well as DSV Cmax and AUC (101%
and 1030%, respectively). The mean t1/2 of DSV increased from
approximately 5 to 90 h. In contrast to the increase in DSV expo-
sures, Cmax and AUC values of DSV metabolite M1 decreased, with
95% lower Cmax and 78% lower AUC values.Journal of Hepatology 20CYP3A and P-gp inhibitor (ketoconazole)
In the presence of ketoconazole, increased Cmax and AUC values
were observed for PTV (37% and 98%, respectively) and ritonavir
(27% and 57%, respectively) and an increased AUC value was
observed for DSV (42%). DSV Cmax (16% increase) and OBV Cmax
and AUC (617% change) were not affected. The mean t1/2 of PTV
was 2-fold longer (13.7 vs. 5.5 h) in the presence of ketoconazole.
Ketoconazole Cmax was not affected (15% increase), but keto-
conazole AUC increased by 117%. The mean t1/2 of ketoconazole
was 4-fold longer (15.7 vs. 3.3 h) in the presence of OBV, PTV/r,
and DSV.
CYP3A and P-gp inducer (carbamazepine)
When the 3D regimen of OBV, PTV/r, and DSV was coadminis-
tered with carbamazepine, decreased Cmax and AUC values were
observed for PTV (66% and 70%, respectively), DSV (55% and 70%,
respectively) and ritonavir (83% and 87%, respectively), and to a
lesser extent, OBV (31% and 30%, respectively) and DSV metabo-
lite M1 (36% lower AUC).
Carbamazepine Cmax and AUC values were not affected (617%
change), but the metabolite carbamazepine-10, 11-epoxide AUC
value decreased by 25%.
CYP2C9 substrate (warfarin)
Coadministration with the 3D regimen of OBV, PTV/r, and DSV
did not affect R- or S-warfarin exposures (612% change in Cmax
and AUC) or PTV, ritonavir, OBV, DSV exposures (67% change in
Cmax and AUC).
CYP2C19 substrate (omeprazole)
In the presence of the 3D regimen of OBV, PTV/r, and DSV, the
Cmax and AUC values of omeprazole were reduced by 38%, but
PTV, ritonavir, OBV, and DSV exposures were relatively
unchanged (619% change in Cmax and AUC).
P-gp substrate (digoxin)
During coadministration with the 3D regimen of OBV, PTV/r, and
DSV, values for digoxin Cmax and AUC (616% increase), C24 (1%
change), and the fraction of unchanged drug eliminated in the
urine (ratio of fraction excreted: 0.98) were essentially
unchanged, as were PTV, ritonavir, OBV, and DSV exposures
(68% change in Cmax and AUC).
OATP1B1/B3 substrate (pravastatin)
Coadministration of pravastatin with the 3D regimen of OBV,
PTV/r, and DSV increased pravastatin Cmax and AUC values by
37% and 82%, respectively, but did not affect PTV, ritonavir,
OBV, or DSV exposures (613% change in Cmax and AUC).
OATP1B1/B3 and BCRP substrate (rosuvastatin)
Rosuvastatin exposures increased in the presence of the 3D reg-
imen of OBV, PTV/r, and DSV: Cmax increased by 613% and AUC
increased by 159%. PTV Cmax and AUC increased by 59% and
52%, respectively, but ritonavir, OBV, and DSV exposures were
unaffected (611% change in Cmax and AUC).15 vol. 63 j 20–29 23
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Fig. 2. Effect of concomitant medications on the Cmax and AUC values of PTV, ritonavir, OBV, and DSV (geometric mean ratio and 90% CI). GMR indicate Cmax and AUC
values for coadministration of the medication with the 3D regimen vs. administration of the 3D regimen alone. For gemﬁbrozil, a PTV/r + DSV regimen was evaluated.
Research ArticleInteractions with commonly used medications
Effects of the 3D regimen of OBV, PTV/r, and DSV on exposures of
medications commonly used in HCV-infected patients are pre-
sented in Fig. 3, and effects of these commonly used medications
on the exposures of the DAAs and ritonavir are presented in Fig. 2.24 Journal of Hepatology 20Addiction treatment medications (methadone and
buprenorphine/naloxone)
Coadministration of the 3D regimen of OBV, PTV/r, and DSV with
methadone did not affect R- or S-methadone exposures (65%15 vol. 63 j 20–29
Geometric mean ratio and 90% CI
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Fig. 3. Effect of the 3D regimen of OBV, PTV/r, and DSV on the Cmax and AUC
values of concomitant medications (geometric mean ratio and 90% CI). GMR
indicate Cmax and AUC values for coadministration of the medication with the 3D
regimen vs. administration of the medication alone.
JOURNAL OF HEPATOLOGYchange in Cmax and AUC). Coadministration had a modest effect
on naloxone exposures (18% and 28% increase in Cmax and AUC,
respectively). In contrast, buprenorphine Cmax and AUC increased
by 118% and 107%, respectively, and norbuprenorphine Cmax and
AUC increased by 107% and 84%, respectively, upon coadminis-
tration. Results from pharmacodynamic measurements indicated
no signiﬁcant changes in pupil diameter, opioid withdrawal scale
score, or desire for drug questionnaire score when methadone or
buprenorphine/naloxone was administered with the 3D regimen,
compared to methadone or buprenorphine/naloxone dosed
alone.
Geometric mean values of Cmax and AUC for PTV, ritonavir,
OBV, and DSV in these studies were comparable to those
observed when the 3D regimen was administered alone in stud-
ies evaluating interactions with duloxetine, escitalopram, alpra-
zolam, and furosemide.
Antidepressants (escitalopram and duloxetine)
In the presence of the 3D regimen of OBV, PTV/r, and DSV, esci-
talopram exposures were not affected (no change in Cmax and
13% decrease in AUC); however, the AUC of metabolite
S-desmethyl citalopram increased by 36%. Coadministration
reduced duloxetine Cmax and AUC by 21% and 25%, respectively,Journal of Hepatology 20but did not affect DAA or ritonavir exposures, except for a 21%
decrease in PTV Cmax in the presence of duloxetine and a 31%
increase in ritonavir Cmax in the presence of escitalopram.
Antihypertensive calcium channel blocker (amlodipine)
Coadministration of amlodipine with the 3D regimen of OBV,
PTV/r, and DSV increased amlodipine Cmax and AUC by 26% and
157%, respectively, and decreased PTV Cmax and AUC by 23%
and 22%, respectively. Ritonavir, OBV, and DSV exposures were
unaffected (67% change in Cmax and AUC).
Anxiolytic/sleep aid (alprazolam and zolpidem)
When coadministered with the 3D regimen of OBV, PTV/r, and
DSV, zolpidem exposures did not change (66% decrease in Cmax
and AUC), alprazolam Cmax was not affected (9% increase), and
alprazolam AUC increased by 34%. DAA and ritonavir exposures
were unaffected by alprazolam or zolpidem (69% change in
Cmax and AUC), except for 37% and 32% decreases in PTV Cmax
and AUC, respectively, in the presence of zolpidem.
Diuretic (furosemide)
In the presence of the 3D regimen of OBV, PTV/r, and DSV, furo-
semide Cmax increased by 42% though furosemide AUC was not
affected (8% increase). Furosemide had minimal impact (614%
change in Cmax and AUC) on PTV, ritonavir, OBV, and DSV
exposures.
Oral contraceptives
Three oral contraceptives were evaluated with the 3D regimen of
OBV, PTV/r, and DSV in the same study: one containing
progestin-only (norethindrone) and two containing a combina-
tion of EE and a progestin (norgestimate or norethindrone). EE
plus norgestimate was also administered with PTV/r and OBV
(without DSV). Enrollment in the EE plus norgestimate arms
was stopped due to safety concerns after enrolling only three
subjects in the OBV, PTV/r, and DSV regimen and six subjects in
the regimen without DSV. Data from these nine subjects were
combined for analyses.
Coadministration of the 3D regimen of OBV, PTV/r, and DSV
with norethindrone did not affect norethindrone, ritonavir,
OBV, or DSV exposures (617% change in Cmax and AUC), but
increased PTV Cmax and AUC by 24% and 23%, respectively.
Norelgestromin, a metabolite of norgestimate, Cmax and AUC
values increased by 101% and 160%, respectively, and norgestrel,
another metabolite of norgestimate, Cmax and AUC values
increased by 126% and 154%, respectively. Coadministration did
not affect exposures of EE (616% change in Cmax and AUC) or
OBV (65% change in Cmax and AUC), but decreased PTV and riton-
avir exposures by up to 34% and decreased DSV exposures by
approximately 52%.
For EE plus norethindrone, coadministration with the 3D reg-
imen of OBV, PTV/r, and DSV did not affect EE Cmax (17% increase),
but increased EE AUC by 22%. Similarly, norethindrone Cmax was
not affected (12% increase), but AUC was increased by 29%. Since
the study was stopped prior to availability of steady-state inter-
action data, these results are based on data available following
the ﬁrst day of co-dosing.15 vol. 63 j 20–29 25
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Tmax, T1/2 and DSV metabolite M1 pharmacokinetics
Across the 13 studies, Tmax and t1/2 (where calculated) values for
the interacting drugs or DAAs were not affected in a meaningful
way, except in the ketoconazole and gemﬁbrozil studies, as
described earlier. In addition, DSV metabolite M1 exposures mir-
rored DSV exposures except for the interaction with gemﬁbrozil,
in which DSV exposures increased and DSV M1 exposures
decreased, and the interaction with carbamazepine, where DSV
M1 exposures decreased to a lesser extent than DSV exposures.
Safety
There were no serious adverse events with the 3D regimen of
OBV, PTV/r, and DSV in any of the studies. In studies other than
the oral contraceptives study discussed below, 2 subjects discon-
tinued study drug due to an adverse event: one due to aspartate
aminotransferase (AST) elevation and one due to pruritus. The
adverse event of AST elevation occurred in a subject who received
a single 10 mg dose of escitalopram on Study Days 1 and 21 and
the 3D regimen on Study Days 7 through 21. The maximum
increase in AST (199 U/L) occurred on Day 21, at which time
the subject was discontinued from study drug. AST levels
returned to normal on Day 26. The adverse event of pruritus
occurred on Study Day 1, 3 h after the subject received a single
dose of PTV/r plus DSV in the gemﬁbrozil study. Study drug
was discontinued, the subject was treated with oral diphenhy-
dramine, and the event resolved on Study Day 6.
In the oral contraceptive study, among subjects who received
the 3D regimen of OBV, PTV/r, and DSV and norethindrone, no
subject prematurely discontinued study drug or experienced
Grade 2 or greater alanine aminotransferase (ALT) elevations. In
subjects who received EE plus norgestimate or norethindrone, 5
of 21 subjects experienced Grade 3/4 ALT elevations. Four of
the ﬁve subjects with these adverse events prematurely discon-
tinued study drug and the ﬁfth subject (on EE plus norethin-
drone) discontinued study drug when the study arm was
stopped on Day 15. The ALT elevations in these subjects normal-
ized after dosing was stopped. In all of these subjects, the ALT ele-
vations were asymptomatic and there were no concurrent
bilirubin elevations P2 times the upper limit of normal.
Across studies, no clinically meaningful changes in vital signs
values, electrocardiogram parameters, or other laboratory values
were observed.Discussion
The potential for interactions with the 3D regimen of OBV, PTV/r,
and DSV was ascertained from mechanistic, in vivo evaluations
using probe substrates/inhibitors/inducers and evaluations of
medications likely to be coprescribed in HCV-infected patients.
Evaluations were conducted with the DAA combination regimen,
rather than with the individual DAAs, to provide ﬁndings that
would be clinically relevant.
Lower and higher doses of PTV, OBV, and DSV have been eval-
uated in HCV-infected subjects that conﬁrm that the changes in
exposures observed with comedications (except carbamazepine
and gemﬁbrozil) in the current studies are not clinically mean-
ingful. The maximum changes in PTV exposures were observed
with ketoconazole (100% higher) and zolpidem (40% lower).26 Journal of Hepatology 20In Phase 2 studies, lower (100 mg) and higher (200 or 250 mg)
doses of PTV have been shown to have comparable efﬁcacy and
acceptable safety proﬁles [15,16]. These doses provided expo-
sures 55% lower (100 mg), 93% higher (200 mg), and 250% higher
(250 mg) than those observed with the 150 mg PTV dose admin-
istered [17].
Changes in OBV exposures in the presence of the concomitant
medications ranged from 11% lower with rosuvastatin to 17%
higher with ketoconazole. OBV doses of 5 mg to 200 mg have
been evaluated with peg-interferon plus ribavirin for 12 weeks
[18]. The safety and efﬁcacy proﬁles across this 5-fold lower
and 8-fold higher range of exposures were comparable to those
observed with the 25 mg dose of OBV.
Changes in DSV exposures ranged from 8% lower with dulox-
etine to 42% higher with ketoconazole. DSV doses of 300 mg BID
to 800 mg BID have also been evaluated with peg-interferon plus
ribavirin for 12 weeks [19,20]. DSV exposures across these doses
ranged from 25% lower to 100% higher than those in the current
studies and no changes in safety or efﬁcacy were observed.
No dose adjustment is required for the DAAs based on the
drug interactions discussed in this report. Carbamazepine and
gemﬁbrozil are contraindicated with the OBV, PTV/r, and DSV
regimen.
For the interacting medications, the clinical relevance of the
magnitude of interaction was determined based on data from
package inserts, regulatory documents, or literature. Dosing rec-
ommendations for medications evaluated in these studies and
other medications with similar metabolic/transporter pathways
were developed (Tables 3 and 4) and are discussed below.
Mechanism-based drug interactions
In the drug-drug interaction study with the potent CYP3A (and
P-gp) inhibitor, ketoconazole, only minimal to modest increases
in DAA or ritonavir exposures were observed. Though no dose
adjustments for the DAAs are required, ketoconazole doses
should be limited to 200 mg per day or less, as ketoconazole
AUC values increased by 117%. The CYP2C8 inhibitor, gemﬁbrozil,
signiﬁcantly increased DSV exposures and coadministration of
gemﬁbrozil and similar strong CYP2C8 inhibitors is
contraindicated.
Carbamazepine, a CYP3A inducer, decreased PTV, ritonavir,
and DSV exposures by 55% to 87%. Hence, carbamazepine and
other strong CYP3A inducers are contraindicated with the 3D reg-
imen of OBV, PTV/r, and DSV due to the potential for loss of
antiviral efﬁcacy.
Exposures of the CYP2C19 substrate, omeprazole, decreased
when omeprazole was administered with the 3D regimen of
OBV, PTV/r, and DSV, indicating the regimen had a mild inductive
effect on CYP2C19. Though a priori dose modiﬁcation is not
required for omeprazole or other CYP2C19 substrates, higher
doses should be considered if clinically indicated. Results from
the study with the CYP2C9 substrate warfarin suggest that the
3D regimen does not induce or inhibit CYP2C9.
In vitro data suggest that PTV, ritonavir, and DSV are potential
inhibitors of P-gp [12]. However, results from the study with
digoxin suggest this is not the case in vivo.
In vitro data also indicate that PTV, ritonavir, and DSV are
BCRP inhibitors, and that PTV is an OATP1B1/B3 inhibitor [12].
Accordingly, exposures of pravastatin (OATP1B1/B3 substrate)
and rosuvastatin (OATP1B1/B3 plus BCRP substrate) showed15 vol. 63 j 20–29
Table 3. Dosing recommendations from mechanism-based drug-drug interactions.
Mechanism evaluated Probe substrate, 
inhibitor, or inducer
Recommendation when coadministered with the 3D regimen
CYP2C8 and OATP1B1 
inhibition
Gemfibrozil* Strong CYP2C8 inhibitor, gemfibrozil, is contraindicated
CYP3A and P-gp inhibition Ketoconazole Limit ketoconazole and itraconazole doses to ≤200 mg per day. Lower doses are 
recommended for posaconazole
CYP3A and P-gp induction Carbamazepine Carbamazepine and other CYP3A inducers (e.g., phenytoin, phenobarbital, 
rifampin) are contraindicated
CYP2C9 inhibition Warfarin No dose adjustment required for warfarin. No interaction expected for other 
CYP2C9 substrates (e.g., NSAIDS including celecoxib and ibuprofen and 
antidiabetics including glimepiride, glipizide, and tolbutamide)
CYP2C19 inhibition/induction 
and effect of acid reducing 
agents
Omeprazole No a priori dose adjustment required; increase dose if clinically indicated for 
omeprazole and other CYP2C19 substrates (e.g., lansoprazole, esomeprazole, 
pantoprazole)
P-gp inhibition Digoxin No dose adjustment required for digoxin. No interaction expected for other P-gp 
substrates (e.g., talinolol)
OATP1B1/B3 and BCRP 
inhibition
Pravastatin Reduce pravastatin dose by half / do not exceed 40 mg/day; lower doses 
recommended for other OATP1B1/B3 substrates (e.g., angiotensin II receptor 
blockers including valsartan, olmesartan, and telmisartan and statins including 
pitavastatin and fluvastatin)
Rosuvastatin Limit rosuvastatin dose to ≤10 mg per day; lower doses recommended for other 
BCRP substrates (e.g., sulfasalazine)
*Evaluated with a PTV/r + DSV regimen only.
Table 4. Dosing recommendations based on drug-drug interactions with commonly used medications.
Drug class Medication Recommendation when coadministered with the 3D regimen
Anti-addictives Methadone No dose adjustment
Buprenorphine No dose adjustment
Naloxone No dose adjustment
Antidepressants Escitalopram No dose adjustment for escitalopram or citalopram
Duloxetine No dose adjustment for duloxetine, fluoxetine, paroxetine or desipramine
Antihypertensives Amlodipine Reduce amlodipine dose by half. Decrease doses of other calcium channel 
blockers (e.g., nifedipine, verapamil, and diltiazem) with clinical monitoring. Avoid 
felodipine and nisoldipine
Anxiolytics/sleep 
aids
Zolpidem No dose adjustment
Alprazolam No dose adjustment; clinical monitoring recommended
Diuretics Furosemide No dose adjustment; clinical monitoring recommended
Oral contraceptives Norethindrone only No dose adjustment
Ethinyl estradiol containing* Contraindicated
*Ethinyl estradiol plus norgestimate interactions were evaluated with PTV/r, OBV ± DSV regimens.
JOURNAL OF HEPATOLOGYclinically signiﬁcant increases. Greater increases in rosuvastatin
exposures (159% to 613%) compared to pravastatin exposures
(37% to 82%) are likely due to the combined effect of
OATP1B1/B3 plus BCRP inhibition for rosuvastatin compared with
OATP1B1/B3 inhibition for pravastatin. Based on the magnitude
of the interactions, the pravastatin dose should be reduced by
half or limited to 40 mg and the rosuvastatin dose should be lim-
ited to 610 mg per day when coadministered with the 3D regi-
men of OBV, PTV/r, and DSV.
Interactions with other commonly used medications
Addiction treatment medications
Patients receiving methadone or buprenorphine/naloxone do not
require dose adjustments of these drugs when coadministeredJournal of Hepatology 20with the 3D regimen of OBV, PTV/r, and DSV. Although increases
in exposures of buprenorphine and its metabolite, norbuprenor-
phine, were observed, these increases did not translate into phar-
macodynamics changes.
Antidepressants
Exposures of escitalopram were minimally affected upon coad-
ministration and no dose modiﬁcation is needed. The 21% to
25% decreases in duloxetine exposures do not necessitate dose
adjustment, as decreases in duloxetine exposures of up to 30%
are not expected to affect efﬁcacy [21].
Antihypertensives
Coadministration of the calcium channel blocker, amlodipine,
with the 3D regimen of OBV, PTV/r, and DSV increased15 vol. 63 j 20–29 27
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amlodipine exposures by 26% to 157%, consistent with
ritonavir-mediated inhibition of the metabolism of this CYP3A
substrate. A 50% reduction in amlodipine dose is recommended
when administered with the 3D regimen.
Anxiolytic/sleep aid
Zolpidem exposures were not affected by coadministration, but
alprazolam AUC showed a modest 34% increase when alprazolam
was coadministered with the 3D regimen of OBV, PTV/r, and DSV.
No a priori dose adjustments are needed for alprazolam, although
clinical monitoring is recommended.
Diuretics
Although the total exposure (AUC) of furosemide was minimally
affected by coadministration with the 3D regimen of OBV, PTV/r,
and DSV, peak exposure (Cmax) increased by 42%. Based on this
modest interaction and the well characterized safety proﬁle of
furosemide, no a priori dose adjustment is needed, but clinical
monitoring is recommended.
Oral contraceptives
EE-containing products are contraindicated with the 3D regimen
of OBV, PTV/r, and DSV due to ALT elevations. The mechanism for
this pharmacodynamic interaction is not clear. The
progestin-only contraceptive, norethindrone, can be adminis-
tered with the 3D regimen.
Conclusions
A comprehensive evaluation of drug-drug interactions for the 3D
regimen of OBV, PTV/r, and DSV and 20 medications was con-
ducted in 13 separate studies. These investigations revealed that
the majority of the commonly used medications can be coadmin-
istered with the 3D regimen without dose adjustment.
Gemﬁbrozil and carbamazepine are contraindicated with the
3D regimen because they alter exposures of the DAAs.
Concomitant administration of EE-containing contraceptives is
contraindicated due to safety reasons though progestin-based
oral contraceptives can be coadministered. Finally, no dose
adjustment is necessary for the 3D regimen when coadministered
with any of the evaluated medications that are not otherwise
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